Uridine

Uridine

SCHEMBL4455604

O=c1ccn([C@H]2O[C@@H](CO)[C@H](O)[C@H]2O)c(=O)[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
SLC28A1 O00337 1/20 1.00
SLC28A2 O43868 1/20 1.00
SLC29A1 Q99808 1/20 1.00
SLC28A3 Q9HAS3 1/20 1.00
P2RY2 P41231 11/20 0.69
P2RY6 Q15077 8/20 0.65
P2RY4 P51582 4/20 0.63
P2RY14 Q15391 7/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Uridine SCHEMBL2114452 1.00 SLC28A1 (1.00) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2
Uridine SCHEMBL360394 1.00 SLC28A1 (1.00) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2
Uridine SCHEMBL16273806 1.00 SLC28A1 (1.00) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2
Uridine SCHEMBL2912983 1.00 SLC28A1 (1.00) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2
Uridine SCHEMBL890304 1.00 SLC28A1 (1.00) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2
Uridine SCHEMBL9945547 1.00 SLC28A1 (1.00) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2
Uridine SCHEMBL2056530 1.00 SLC28A1 (1.00) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2
Uridine SCHEMBL2056634 1.00 SLC28A1 (1.00) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2
Uridine SCHEMBL20987631 1.00 SLC28A1 (1.00) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2
Uridine SCHEMBL8590899 1.00 SLC28A1 (1.00) SLC28A1SLC28A2SLC29A1SLC28A3P2RY2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107427529-A N4-hydroxycytidine and derivatives and antiviral uses related thereto 埃莫里大学 2017-12-01 CN disclosed
EP-2054076-A2 COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS United Therapeutics Corporation (US) 2009-05-06 EP disclosed
WO-2008063727-A2 COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS UNITED THERAPEUTICS CORPORATION (US) 2008-05-29 WO disclosed